IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima

Padova, Veneto 35128

0 studies enrolling now · 3 studies all time

What they study most

Carcinoma, Hepatocellular, Prostatic Neoplasms, Castration-Resistant, Renal Cell Carcinoma

Studies at this site

• A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen — Completed
• A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma — Completed
• A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy — Stopped early